The current financial score of Fortress Biotech Inc is 6.76. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 18.72M, representing a year-over-year increase of 14.04%, while its net profit experienced a year-over-year increase of 118.54%.
The current valuation score of Fortress Biotech Inc is 9.70. Its current P/E ratio is 0.61, which is 59.39% below the recent high of 0.97 and 7206.58% above the recent low of -43.21.
The current earnings forecast score of Fortress Biotech Inc is 8.00. The average price target is 5.00, with a high of 5.00 and a low of 5.00.
The current price momentum score of Fortress Biotech Inc is 3.84. Currently, the stock price is trading between the resistance level at 2.70 and the support level at 2.15, making it suitable for range-bound swing trading.
The current institutional shareholding score of Fortress Biotech Inc is 3.00. The latest institutional shareholding proportion is 18.14%, representing a quarter-over-quarter decrease of 31.58%. The largest institutional shareholder is James Simons, holding a total of 86.39K shares, representing 0.00% of shares outstanding, with 378.95% increase in holdings.
The current risk assessment score of Fortress Biotech Inc is 3.97. The company's beta value is 1.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.